17ohp Compounded denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for 17ohp compounded are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This as Experimental or Investigational

Blue Cross Blue Shield applies an "experimental or investigational" (E&I) denial when it concludes that a treatment lacks sufficient evidence to meet its clinical-coverage standard. For compounded 17-hydroxyprogesterone caproate, this denial typically arises because the compounded formulation is not itself FDA-approved, and BCBS's coverage policy may require either FDA approval or a specific evidence threshold that the insurer contends has not been met for compounded versions.

This denial is commonly appealed successfully because the clinical evidence base for the underlying compound is well-established in the obstetric literature, and major professional obstetric societies have issued guidance on its use. The appeal must reframe the question: the issue is not whether the therapy is experimental, but whether the compounded formulation for your documented clinical indication meets the insurer's own evidence criteria.

## Federal Appeal Rights

• ACA §2719 external review: E&I denials are among the most frequently overturned at external review. An Independent Review Organization reviews the medical evidence independently of the insurer. Request external review in writing if internal appeal fails — the window is typically around four months from denial, per your plan documents.
• ERISA §503: For self-funded plans, the plan must provide a full and fair review with specific written reasoning tied to the evidence standard applied.
• Expedited review: Available if delay poses a risk to health — submit simultaneously with internal appeal.

## Concrete Appeal Steps

1. Request the specific clinical-coverage policy BCBS applied, and the evidence standard it uses to define "experimental." 2. Ask your prescriber to gather peer-reviewed literature and applicable guideline statements from the relevant professional obstetric organization supporting the use of this compound for your indication. 3. Submit an internal appeal with a prescriber letter addressing each element of the insurer's evidence standard. 4. If denied internally, file for external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Obstetric records establishing the indication.
• Prior-treatment history: Any other agents tried, with dates and outcomes.
• Clinical-severity documentation: Chart entries quantifying risk factors your prescriber used to justify this therapy.
• Prescriber medical-necessity letter: Should specifically rebut the E&I determination by referencing applicable clinical-practice guidelines (cite the organization, not specific numbers) and explaining why the evidence base supports this use.
• Published guideline references: Statements from the applicable professional obstetric society — your prescriber or pharmacist can identify the relevant organization.

## Criteria-Mapping Structure

| BCBS Evidence Criterion (from their policy) | Supporting Evidence for Your Case | |---|---| | Copy each requirement from the E&I section of the coverage policy | Prescriber letter, guideline citations, chart documentation | | Any "accepted medical practice" language | Applicable society guideline organization and its position on this use |

The goal is to demonstrate point-by-point that the insurer's own evidence standard is satisfied. Do not rely on generalities — map each policy requirement to a specific document.